Presepsin a ‘Robust’ Biomarker of Early-Onset Sepsis
Presepsin holds promise as a biomarker for early-onset sepsis (EOS), a systematic review and meta-analysis confirmed. Across a dozen clinical trials, presepsin had a pooled sensitivity of 0.93 for the primary analysis of culture-proven sepsis (95% CI 0.86-0.96), a pooled specificity of 0.91 (95% CI 0.85-0.95), and a pooled diagnostic odds ratio (DOR) of 131.7 […]